STOCK TITAN

Genprex (GNPX) Stock News, Mar-May 2025

GNPX NASDAQ

Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.

Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.

Rhea-AI Summary
Genprex (NASDAQ: GNPX) has signed a new Sponsored Research Agreement (SRA) with the University of Pittsburgh to study GPX-002, its gene therapy treatment for Type 1 (T1D) and Type 2 diabetes (T2D) in animal models. Previous preclinical data showed statistically significant improvements in insulin requirements, c-peptide levels, and glucose tolerance. GPX-002 uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. In T1D, it transforms alpha cells into functional beta-like cells that produce insulin while potentially evading immune response. For T2D, the therapy aims to rejuvenate exhausted beta cells. The treatment can be administered in humans through routine endoscopy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
none
-
Rhea-AI Summary
Genprex (NASDAQ: GNPX) has secured an exclusive patent license agreement with UTHealth Houston for its lead drug candidate, Reqorsa® Gene Therapy, targeting glioblastoma treatment. The agreement grants Genprex exclusive commercial rights and patent exclusivity for using REQORSA in treating glioblastoma, the most aggressive and common primary brain tumor in adults. The company previously reported positive preclinical data in October 2024, where researchers observed that REQORSA significantly reduced glioblastoma cell viability and suppressed cell migration. The treatment works by restoring TUSC2 expression, which has been identified as a novel tumor suppressor for glioblastoma. These promising in vitro results support further evaluation using mouse models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.68%
Tags
none
-
Rhea-AI Summary

Genprex announced positive preclinical data for their Reqorsa® Gene Therapy in treating Ras inhibitor resistant lung cancer at the 2025 AACR Annual Meeting in Chicago. The research focused on treating KRASG12C mutant non-small cell lung cancer (NSCLC).

Key findings showed that Reqorsa effectively overcomes resistance to LUMAKRAS® (sotorasib) in NSCLC mouse models. The therapy demonstrated significant results both alone and in combination with sotorasib:

  • Reduced colony formation and increased cancer cell death in resistant cell lines
  • Decreased viability of resistant organoids
  • Showed strong anti-tumor effects in controlling tumor growth
  • Achieved synergistic anti-tumor effects when combined with sotorasib

The research suggests Reqorsa's potential as a treatment for Ras inhibitor resistant lung cancer, either as a standalone therapy or in combination with Ras inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
Rhea-AI Summary

Genprex announced that its research collaborators will present positive preclinical data for their diabetes gene therapy drug candidate GPX-002 at the ASGCT 28th Annual Meeting in New Orleans this May.

The research focuses on a novel gene therapy using recombinant adeno-associated virus (rAAV) to treat diabetes mellitus. Key findings show that retrograde intraductal infusion of rAAV6 successfully delivered Pdx1 and MafA genes, converting alpha cells into insulin-secreting beta-like cells.

Testing on non-human primates demonstrated:

  • Improved glucose tolerance and reduced insulin needs one month post-infusion
  • Durable effects using AAV6 capsid with endocrine-specific promoters
  • Successful immune response management using temporary immunosuppression
  • Sustained therapeutic effects even after stopping immunosuppression

The research represents a potential breakthrough in diabetes treatment, with results showing sustained therapeutic effects without long-term immunosuppression requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
conferences clinical trial
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) has signed an exclusive patent license agreement with NYU Langone Health for Reqorsa® Gene Therapy to treat mesothelioma. The therapy shows promising preclinical results in treating Malignant Pleural Mesothelioma (MPM).

Research data presented at the 2024 EORTC-NCI-AACR Symposium demonstrated that REQORSA significantly decreased cell proliferation and invasion while increasing cell apoptosis in MPM cell lines. The therapy utilizes the TUSC2 tumor suppressor gene, which is downregulated in 84% of mesotheliomas.

Genprex formed a Mesothelioma Clinical Advisory Board in 2024 with four leading researchers to support its preclinical program. According to CDC data, mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months and a 3-year survival rate of 23% with treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
none
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) has been selected to present at the 2025 ASCO Annual Meeting in Chicago, showcasing their Acclaim-3 Phase 1/2 clinical trial design. The presentation will focus on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

The presentation is scheduled for May 31, 2025, from 1:30 to 4:30 p.m. CT, and will be delivered by Dr. Bo Wang from Oncology Associates of Oregon. The abstract will be featured in the Trials in Progress poster session, highlighting the company's innovative approach in cancer treatment development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.62%
Tags
conferences clinical trial
Rhea-AI Summary

Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).

The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary

Genprex announced that its research collaborators will present positive preclinical data for Reqorsa® Gene Therapy at the 2025 AACR Annual Meeting in Chicago. The study focuses on treating KRASG12C mutant non-small cell lung cancer (NSCLC), particularly addressing resistance to Lumakras® (sotorasib).

The preclinical data demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy both as a standalone therapy and in combination with sotorasib in resistant tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences clinical trial
-
Rhea-AI Summary

Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data for GPX-002, their diabetes gene therapy drug candidate, at the 2025 American Diabetes Association 85th Scientific Sessions in Chicago.

GPX-002 is being developed as a potential disease-modifying therapy for both Type 1 and Type 2 diabetes, aiming to eliminate the need for daily blood glucose monitoring and insulin replacement therapy. Recent company developments include:

  • Signing an amended license agreement for multiple diabetes gene therapy technologies
  • Formation of Convergen Biotech subsidiary focused on diabetes program development
  • Addition of research on re-dosable non-viral delivery systems

Two presentations are scheduled: a poster presentation on lipid nanoparticles for islet cell transfection, and an oral presentation on AAV-mediated gene therapy treatment in non-human primates with streptozotocin-induced diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
conferences clinical trial
Rhea-AI Summary

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced its participation in BIO Europe Spring 2025, scheduled for March 17-19 in Milan, Italy. Ryan Confer, President and CEO, and Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will represent the company.

The executives will be available for one-on-one meetings with industry groups to discuss Genprex's gene therapies for cancer and diabetes. The conference is expected to attract over 3,700 executives from biotech, pharma, and finance sectors, facilitating more than 20,000 one-on-one meetings.

Interested parties can schedule meetings through the conference portal or by contacting Genprex's Investor Relations at investors@genprex.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
conferences

FAQ

What is the current stock price of Genprex (GNPX)?

Genprex (GNPX) last closed at $1.90.

What is the market cap of Genprex (GNPX)?

The market cap of Genprex (GNPX) is approximately $1.6M.